Meridiano

Add Article

No Image Available

Article Details

Title

Article: In a first for China, Neuracle’s implantable brain-computer interface wins approval

Impact Score

6 / 10

AI Summary (Processed Content)

Neuracle, a Chinese BCI startup, has received regulatory approval for its implantable brain-computer interface, described as the first globally approved commercial invasive BCI product for patients. The coin-sized device sits on the brain's surface without penetrating tissue and is designed to interpret neural signals to control hand movements.

This milestone has boosted investor sentiment, lifting shares of related companies and highlighting the growing momentum of China's BCI sector. Neuracle, which is also pursuing an IPO on Shanghai's Star Market, represents China's emerging challenge to global leaders like Neuralink.

The main topics covered are Neuracle's regulatory approval, the technical description of the BCI device, the market reaction in China, and the competitive landscape of the BCI industry.

Original URL

https://www.scmp.com/business/banking-finance/article/3346495/first-china-neuracles-implantable-brain-computer-interface-wins-approval?utm_source=rss_feed

Source Feed

Tech - South China Morning Post

Published Date

2026-03-13 09:30

Fetched Date

2026-03-13 07:30

Processed Date

2026-03-13 07:32

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

In a first for China, Neuracle’s implantable brain-computer interface wins approval
China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth
China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, are gaining momentum as regulatory support and fresh capital fuel growth.
Shares of BCI companies rose on mainland Chinese exchanges on Friday, with Shenzhen-listed Inkon Life Technology surging more than 10 per cent.
The approval awarded to Neuracle, a private firm founded in 2011, marked the first time globally that an invasive BCI could be sold and used on patients as a commercial product, according to China’s National Medical Products Administration.
The company’s founder, Xu Honglai, earned a PhD in biomedical engineering from Tsinghua University.
Last month, Neuracle, which develops and sells scientific research equipment, launched its listing process on the Star Market of the Shanghai Stock Exchange by signing an initial public offering tutoring agreement with Citic Securities.
The newly approved implantable BCI hand motor function system was described by the company as a coin-sized wireless device placed on the brain’s outer surface without penetrating tissue, designed to read patients’ neural signals and translate them into hand movements.